ReviewAnnals of biomedical engineering2025
Molecular Dynamics Simulations and Their Novel Applications in Drug Delivery for Cancer Treatment: A Review.
Review in Annals of biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Developing virtual physiology of human tumor tissue for malignancy assessment.NPJ precision oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular Dynamics (MD) simulations have emerged as a vital tool in optimizing drug delivery for cancer therapy, offering detailed atomic-level insights into the interactions between drugs and their carriers. Unlike traditional experimental methods, which can be resource-intensive and time-consuming, MD simulations provide a more efficient and precise approach to studying drug encapsulation, stability, and release processes. These simulations are essential for designing effective drug carriers and gaining a deeper understanding of the molecular mechanisms that influence drug behavior in biological systems. Recent research has highlighted the broad applicability of MD simulations in assessing different drug delivery systems, such as functionalized carbon nanotubes (FCNTs), chitosan-based nanoparticles, metal-organic frameworks (MOFs), and human serum albumin (HSA). FCNTs are known for their high drug-loading capacity and stability, while biocompatible carriers like HSA and chitosan are favored for their biodegradability and reduced toxicity. Case studies involving anticancer drugs, including Doxorubicin (DOX), Gemcitabine (GEM), and Paclitaxel (PTX), showcase how MD simulations can improve drug solubility and optimize controlled release mechanisms. Although the computational complexity of these simulations presents challenges, advances in high-performance computing and machine learning techniques are driving significant progress. These innovations are facilitating the development of more targeted and efficient cancer therapies. By combining MD simulations with experimental validation, researchers are enhancing predictive models and accelerating the creation of next-generation drug delivery systems.
Indexed as
Identifiers
41023346What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.